ThermoGenesis Corp, a leading supplier of innovative products and services that process and store adult stem cells, said that the company has introduced a new line of veterinary point-of-care (POC) products under the Vantus brand. Unveiling of the first product, Res-Q60v ePRP, is taking place at this week's 54th Annual Convention of the American Association of Equine Practitioners (AAEP).

The initial product offering, Res-Q60v ePRP will be used for producing equine platelet-rich plasma (PRP) from 60 mL of blood. PRP is being used to treat ligament and tendon injuries in performance horses. The device enables veterinarians to prepare high quality PRP at the point of care in less than 15 minutes. The company plans to introduce Res-Q60v eBMC, another equine product for producing high quality bone marrow concentrate, during calendar 2009. Many performance horses suffer orthopaedic injuries and these biological products are emerging as a new means for the treatment to expedite healing of injured ligaments and tendons.

"We have been looking forward to launching the Res-Q60v ePRP at this prestigious equine industry event and commencing commercial sales in the early part of next year. The response among AAEP attendees was favorable and we look forward to participating in the veterinary market as an additional source of revenue for the company," said Matthew Plavan, chief executive officer of ThermoGenesis.

"We appreciate the collaborative efforts with the University of California, Davis, School of Veterinary Medicine who consulted with us in our development of this technology specifically for equine applications," Plavan added.

"PRP delivers a high concentration of growth factors to damaged tissue where they stimulate the healing cascade. PRP also has the potential to minimize scarring and decrease the reinjury rate," noted Larry Galuppo, DMV, associate professor and chief of Equine Surgery in the Department of Surgical and Radiological Sciences at the University of California, Davis, School of Veterinary Medicine.

"We are actively defining our marketing strategy to prioritize those opportunities that will enable ThermoGenesis to both meet its financial goals and to expand its leadership position in cell processing. The launch of the Res-Q technology is a device that addresses an existing and meaningful market opportunity," Plavan noted.

ThermoGenesis is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products.